EPO and anemia: Moreover, the present iron deficiency (either true or functional) with anemia or EPO administration, contributes to high iFGF23 levels, that influence phosphate, PTH, and vitamin D metabolism defined as chronic kidney disease-mineral and bone disorder (CKD-MBD).